SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 3, 2019
Heat Biologics, Inc.
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
801 Capitola Drive
Durham, NC 27713
(Address of principal executive offices and zip code)
(Registrants telephone number including area code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Common Stock, $0.0002 par value per share
The Nasdaq Capital Market
Item 8.01 Other Events.
On June 3, 2019, Heat Biologics, Inc. (the Company) issued a press release announcing that on June 2, 2019 members of the management team of the Company and certain clinical investigators in its ongoing Phase 2 study investigating HS-110 in combination with Bristol-Myers Squibbs anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) presented the Poster entitled “Viagenpumatucel-L (HS-110) plus Nivolumab In Patients With Advanced Non-Small Cell Lung Cancer After Checkpoint Inhibitor Treatment Failure” at the American Society of Clinical Oncology’s 2019 Annual Meeting held in Chicago, Illinois.
In response to questions raised from investors following the Company’s announcement today, the Company discloses that it has no current plans to raise funds through sales under its At The Market Issuance Sales (ATM) Facility or conduct a financing. The Company had approximately $23.5 million in cash, cash equivalents and short-term investments as of March 31, 2019 and expects to receive an additional $6.9 million in CPRIT grant funding.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 3, 2019
HEAT BIOLOGICS, INC.
/s/ Jeffrey Wolf
Chairman, President and